Pasireotide—a novel somatostatin receptor ligand after 20 years of use
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Pasireotide, a novel multireceptor-targeted somatostatin receptor ligand (SRL) is characterized by a higher affinity to somatostatin receptor type 5 than type 2, unlike first-generation SRLs. Because of the broader binding profile, pasireotide has been suggested to have a greater clinical efficacy in acromegaly than first-generation SRLs and to be efficacious in Cushing’s disease. The consequence of this binding profile is the increased blood glucose level in some patients. This results from the inhibition of both insulin secretion and the incretin effect and only a modest suppression of glucagon. A monthly intramuscular formulation of long-acting release pasireotide has been approved for both acromegaly and Cushing’s disease treatment. This review presents data on the efficacy and safety of pasireotide treatment mostly in patients with acromegaly and Cushing’s disease. Moreover, other possible therapeutic applications of pasireotide are mentioned.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2021
American Diabetes Association (2021) · Diabetes Care · doi:10.2337/dc21-s002 · Cited by 3,116
Bruns, C., Lewis, I., Briner, U., Meno-Tetang, G., & Weckbecker, G. (2002) · European Journal of Endocrinology · doi:10.1530/eje.0.1460707 · Cited by 692 · cited 4×
“PAS targets four of the five SST receptor subtypes, with the highest affinity for SSTR5, followed by SSTR2 [8].”
BackgroundInfluentialA 12-month phase 3 study of pasireotide in Cushing's disease
Colao, A., Petersenn, S., Newell-Price, J., Findling, J. W., Gu, F., Maldonado, M., Schoenherr, U., Dipl.-Biol., Mills, D., Salgado, L. R., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1105743 · Cited by 628
Pasireotide (SOM230): Development, mechanism of action and potential applications
Schmid, H. A. (2008) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2007.09.006 · Cited by 290 · cited 1×
“PAS shows a half-life of 7–11 h following a single subcutaneous administration [8, 25].”
BackgroundIs diabetes in Cushing’s syndrome only a consequence of hypercortisolism?
Giordano, C., Guarnotta, V., Pivonello, R., Amato, M. C., Simeoli, C., Ciresi, A., Cozzolino, A., & Colao, A. (2014) · European Journal of Endocrinology · doi:10.1530/eje-13-0754 · Cited by 79
Use of late-night salivary cortisol to monitor response to medical treatment in Cushing's disease
Newell-Price, J., Pivonello, R., Tabarin, A., Fleseriu, M., Witek, P., Gadelha, M. R., Petersenn, S., Tauchmanova, L., Ravichandran, S., Gupta, P., et al. (2020) · European Journal of Endocrinology · doi:10.1530/eje-19-0695 · Cited by 60
Self-citation
Cited by
From geroscience to precision geromedicine: Understanding and managing aging
Kroemer, G., Maier, A. B., Cuervo, A. M., Gladyshev, V. N., Ferrucci, L., Gorbunova, V., Kennedy, B. K., Rando, T. A., Seluanov, A., Sierra, F., et al. (2025) · Cell · doi:10.1016/j.cell.2025.03.011 · Cited by 395
Ata, F., Choudry, H., Khan, A. A., Anum, Khamees, I., Al‐sadi, A., Mohamed, A., Malkawi, L., & Aljaloudi, E. (2024) · Endocrinology, Diabetes & Metabolism · doi:10.1002/edm2.471 · Cited by 18
Metadata
- Authors
- Bolanowski, M., Kałużny, M., Witek, P., & Jawiarczyk-Przybyłowska, A.
- Venue
- Reviews in Endocrine and Metabolic Disorders
- Published
- 2022-01-24
- Volume
- 23
- Issue
- 3
- Pages
- 601-620
- ISSN
- 1389-9155 (ISSN-L)
- 1573-2606
- OpenAlex
- W4206989655
- Cited by
- 66
- References
- 6
- FWCI
- 8.28
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pasireotide—a novel somatostatin receptor ligand after 20 years of use. https://app.cochat.ai/papers/10.1007/s11154-022-09710-3
- The paper
- Bolanowski, M., Kałużny, M., Witek, P., & Jawiarczyk-Przybyłowska, A. (2022). Pasireotide—a novel somatostatin receptor ligand after 20 years of use. Reviews in Endocrine and Metabolic Disorders. https://doi.org/10.1007/s11154-022-09710-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.